Roche posts in­ter­im OS da­ta from PhI­II TIG­IT tri­al af­ter leak — and an­a­lysts say it bodes well for fi­nal read­out

Roche has post­ed a snap­shot from a close­ly-watched Phase III tri­al of its TIG­IT an­ti­body af­ter an “in­ad­ver­tent dis­clo­sure.” Al­though the over­all sur­vival da­ta are still not ma­ture, an­a­lysts be­lieve the num­bers so far point to a pos­i­tive trend in non-small cell lung can­cer.

At the sec­ond in­ter­im analy­sis of Roche’s SKY­SCRAPER-01 tri­al, me­di­an OS es­ti­mate was 22.9 months for pa­tients who were giv­en the TIG­IT drug, tiragolum­ab, and the PD-L1 in­hibitor Tecen­triq, com­pared to 16.7 months for the Tecen­triq monother­a­py arm. That yields a haz­ard ra­tio of 0.81, Roche dis­closed Wednes­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER